BALTIMOREPhysicians should consider a biopsy to confirm a
prostate cancer diagnosis when a prostate-specific antigen (PSA) test
reading is at least 4.0 ng/mL, the PSA level of a patient
significantly increases from one test to the next, or a digital
rectal examination is abnormal, according to a Best Practice Policy
released by the American Urological Association (AUA).
The policy report, which was developed by a multidisciplinary panel
of physicians, appears in the February issue of the journal ONCOLOGY,
and is available online at www.cancernetwork.com.
The policy states that decisions regarding PSA testing should be
individualized, and benefits and consequences discussed with the
patient before testing is performed. Generally, the AUA
recommendation is that all men with at least a 10-year life
expectancy should be offered regular PSA testing beginning at age 50,
and earlier in high-risk men.